European Lung Cancer Congress | Conference

Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung Cancer

April 16th 2016

Raffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).

Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC

April 16th 2016

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

Liquid Biopsy Offers Alternative to Predicting Osimertinib Response in NSCLC

April 16th 2016

Plasma genotyping can, in most cases, identify T790M-positivity in non-small cell lung cancer, which gives patients the option of receiving the targeted therapy osimertinib without the need for a tumor biopsy, according Geoffrey R. Oxnard, MD.

Combined Durvalumab/Gefitinib Combo Shows Promise in EGFR-Mutated NSCLC

April 15th 2016

The first analysis of a trial investigating durvalumab in combination with gefitinib (Iressa) showed encouraging anti-tumor activity and tolerability in patients with non–small cell lung cancer and EGFR mutations that were tyrosine-kinase inhibitor-naïve.

Dr. Paz-Ares on Connection of EGFR-Expression and Necitumumab Response in NSCLC

April 15th 2016

Luis Paz-Ares, MD, PhD, Professor of Medicine at Hospital Universitario 12 de Octubre in Madrid, Spain, discusses a subgroup analysis of patients with EGFR-expressing tumors from the SQUIRE trial, a phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone as first-line treatment for patients with stage IV squamous non-small cell lung cancer (NSCLC).

Dr. Suresh Ramalingam on Frontline Osimertinib in EGFR+ NSCLC

April 15th 2016

Suresh Ramalingam, MD, professor of Hematology and Medical Oncology at Emory School of Medicine and deputy director of Winship Cancer Institute, discusses first-line treatment with single-agent osimertinib in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Update Identifies Best Responders to Necitumumab in NSCLC

April 15th 2016

Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.

Novel Vaccine Added to Chemotherapy Improves Patient Outcomes in Mesothelioma

April 15th 2016

The first report of results from a phase Ib clinical trial evaluating CRS-207, a live, attenuated, double-deleted Listeria monocytogenes vaccine, in combination with pemetrexed and cisplatin, demonstrated the effectiveness of this approach for patients with malignant pleural mesothelioma.

Third-Generation EGFR TKIs Move to Frontline in Lung Cancer

April 14th 2016

A new generation of EGFR-targeted TKIs are poised to displace traditional agents as frontline therapies for patients with lung cancer.

Dr. John Haanen on the Role of PD-L1 in Lung Cancer

April 14th 2016

John Haanen, MD PhD, epartment of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, discussed the role of PD-L1 as a biomarker in lung cancer.

Frontline Osimertinib Approaches 80% Response in EGFR+ NSCLC

April 14th 2016

First-line treatment with single-agent osimertinib (Tagrisso) induced a response rate of 77% in patients with EGFR-mutated non–small cell lung cancer.

Dr. Thierry Jahan on CRS-207 With Chemotherapy in Mesothelioma

April 14th 2016

Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).

High Response Rates Observed With BI-1482694 in T790M+ NSCLC

April 14th 2016

Patients with non-small cell lung cancer who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).

NEXT PAGE
PREVIOUS PAGE
x